CGON
COM:CGONCOLOGY
CG Oncology
- Stock
Last Close
32.34
22/11 21:00
Market Cap
2.19B
Beta: -
Volume Today
397.20K
Avg: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|
average inventory | ||||
average payables | 994.00K - | 2.11M 112.63% | ||
average receivables | 152.50K - | 197.50K 29.51% | ||
book value per share | 0.60 - | 1.88 210.98% | 42.67 2,171.34% | |
capex per share | 0.00 - | 0.00 85.57% | ||
capex to depreciation | 9.70 - | 0.93 90.38% | ||
capex to operating cash flow | -0.01 - | -0.00 93.39% | ||
capex to revenue | 0.01 - | 0.07 682.71% | ||
cash per share | 0.80 - | 2.15 167.65% | 43.33 1,912.51% | |
days of inventory on hand | ||||
days payables outstanding | 36.61K - | 23.97K 34.53% | ||
days sales outstanding | 0.07 - | 579.03 821,490.05% | 164.61 71.57% | |
debt to assets | 0.26 - | 0.10 60.10% | ||
debt to equity | 0.38 - | 0.12 67.70% | ||
dividend yield | ||||
earnings yield | -0.01 - | -0.01 176.06% | -0.30 2,010.07% | |
enterprise value | 2.44B - | 2.41B 1.38% | 153.18M 93.63% | |
enterprise value over ebitda | -193.61 - | -68.26 64.74% | -2.76 95.95% | |
ev to operating cash flow | -178.61 - | -80.69 54.82% | -3.35 95.84% | |
ev to sales | 235.45 - | 12.59K 5,248.05% | 750.86 94.04% | |
free cash flow per share | -0.21 - | -0.45 116.84% | -10.55 2,257.04% | |
free cash flow yield | -0.01 - | -0.01 116.84% | -0.28 2,257.04% | |
graham net net | 0.53 - | 1.82 244.45% | 40.00 2,100.27% | |
graham number | 1.62 - | 4.74 193.00% | 103.80 2,089.22% | |
income quality | 1.06 - | 0.84 20.93% | 0.94 11.76% | |
intangibles to total assets | 0 - | 0 | 0 | |
interest coverage | -27.95 - | -35.25K 125,998.25% | ||
interest debt per share | 0.24 - | 0.23 2.41% | ||
inventory turnover | ||||
invested capital | 52.63M - | 132.28M 151.34% | 180.36M 36.34% | |
market cap | 2.48B - | 2.48B 0% | 160.98M 93.50% | |
net current asset value | 39.97M - | 124.64M 211.85% | 179.61M 44.11% | |
net debt to ebitda | 3.03 - | 2.04 32.63% | 0.14 93.10% | |
net income per share | -0.19 - | -0.53 176.06% | -11.22 2,010.07% | |
operating cash flow per share | -0.20 - | -0.45 118.28% | -10.55 2,258.15% | |
payables turnover | 0.01 - | 0.02 52.74% | ||
receivables turnover | 5.18K - | 0.63 99.99% | 2.22 251.76% | |
research and ddevelopement to revenue | 1.77 - | 151.98 8,493.55% | 224.27 47.56% | |
return on tangible assets | -0.22 - | -0.24 9.66% | -0.24 1.67% | |
revenue per share | 0.16 - | 0.00 98.16% | 0.05 1,543.33% | |
roe | -0.32 - | -0.28 11.23% | -0.26 7.10% | |
roic | -0.23 - | -0.25 10.67% | -0.30 19.76% | |
sales general and administrative to revenue | 0.45 - | 33.55 7,381.34% | 48.53 44.66% | |
shareholders equity per share | 0.60 - | 1.88 210.98% | 42.67 2,171.34% | |
stock based compensation to revenue | 0.11 - | 3.54 3,196.74% | 7.49 111.63% | |
tangible asset value | 40.25M - | 125.18M 210.98% | 184.79M 47.62% | |
tangible book value per share | 0.60 - | 1.88 210.98% | 42.67 2,171.34% | |
working capital | 52.43M - | 131.78M 151.33% | 179.87M 36.49% |
All numbers in USD (except ratios and percentages)